0.69

9.58% 0.0603

After Hours: .68 -0.010 -1.45%

Talphera Inc (TLPH)

Overview News Price History Discussions Forecast

Talphera Inc stock is traded at $0.69, with a volume of 30,965. It is up +9.58% in the last 24 hours and up +11.29% over the past month. Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Previous Close:

$0.6297

Open:

$0.6297

24h Volume:

30,965

Relative Volume:

0.32

Market Cap:

$11.75M

Revenue:

$2.82M

Net Income/Loss:

$-14.20M

P/E Ratio:

-0.8118

EPS:

-0.85

Net Cash Flow:

$-15.13M

1W Performance:

-1.40%

1M Performance:

+11.29%

6M Performance:

-20.87%

1Y Performance:

-23.01%

1-Day Range:

$0.602

$0.69

1-Week Range:

$0.54

$0.71

52-Week Range:

$0.501

$1.61

Talphera Inc Stock (TLPH) Company Profile

Name

Talphera Inc

Sector

Healthcare (1177)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

650-216-3500

Address

1850 GATEWAY DRIVE, SAN MATEO

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

TLPH's Discussions on Twitter

Compare TLPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TLPH Talphera Inc	0.69	11.75M	2.82M	-14.20M	-15.13M	-0.85
ZTS Zoetis Inc	174.12	78.56B	9.15B	2.43B	2.31B	5.32
TAK Takeda Pharmaceutical Co Adr	13.61	43.15B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	9.51	43.00B	14.26B	1.55B	0	0.3383
TEVA Teva Pharmaceutical Industries Ltd Adr	17.29	19.59B	16.54B	-1.64B	749.00M	-1.45
NBIX Neurocrine Biosciences Inc	150.51	15.24B	2.24B	385.90M	440.10M	3.73

Talphera Inc Stock (TLPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Jul-20-20	Downgrade	Credit Suisse	Neutral → Underperform
Nov-11-19	Downgrade	Credit Suisse	Outperform → Neutral
Aug-05-19	Resumed	Credit Suisse	Outperform
Jul-10-19	Resumed	Credit Suisse	Outperform
Apr-24-19	Resumed	B. Riley FBR	Buy
Feb-15-19	Initiated	Credit Suisse	Outperform
Oct-23-18	Initiated	B. Riley FBR	Buy
Oct-13-17	Downgrade	Jefferies	Buy → Hold
Oct-13-17	Reiterated	RBC Capital Mkts	Outperform
Jul-14-17	Resumed	Jefferies	Buy
Sep-15-16	Reiterated	ROTH Capital	Buy
Aug-05-16	Downgrade	Stifel	Buy → Hold
Oct-30-15	Upgrade	Jefferies	Hold → Buy
Oct-05-15	Reiterated	ROTH Capital	Buy
Sep-02-15	Initiated	H.C. Wainwright	Buy
Jul-10-15	Resumed	ROTH Capital	Buy
May-06-15	Reiterated	Mizuho	Neutral
May-05-15	Reiterated	RBC Capital Mkts	Outperform
Mar-10-15	Reiterated	RBC Capital Mkts	Outperform
Mar-09-15	Downgrade	Mizuho	Buy → Neutral

View All

Talphera Inc Stock (TLPH) Latest News

Jan 30, 2025

FDA to review Talphera's request to amend NEPHRO study By Investing.com - Investing.com Canada

Jan 14, 2025

FDA to review Talphera’s request to amend NEPHRO study By Investing.com - Investing.com Nigeria

Jan 14, 2025

FDA to review Talphera's request to amend NEPHRO study - Investing.com

Jan 14, 2025

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study - The Eastern Progress Online

Jan 14, 2025

Dec 26, 2024

TLPH stock touches 52-week low at $0.6 amid market shifts - Investing.com UK

Dec 26, 2024

Dec 17, 2024

TLPH stock touches 52-week low at $0.61 amid market challenges - Investing.com

Dec 17, 2024

Dec 12, 2024

Talphera faces Nasdaq delisting over share price rule - Investing.com

Dec 12, 2024

Dec 11, 2024

Talphera faces Nasdaq delisting over share price rule By Investing.com - Investing.com UK

Dec 11, 2024

Acelrx Announces Dsuvia® Milestone C Approval; Provides Revenue Guidance for the First Quarter 2020 - Marketscreener.com

Dec 11, 2024

Dec 07, 2024

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024 - Kilgore News Herald

Dec 07, 2024

Dec 06, 2024

Talphera CEO Vincent J. Angotti acquires $3,199 in common stock - Investing.com

Dec 06, 2024

Talphera CEO Vincent J. Angotti acquires $3,199 in common stock By Investing.com - Investing.com UK

Dec 06, 2024

Dec 02, 2024

Talphera CEO Vincent J. Angotti buys $3,649 in company stock By Investing.com - Investing.com Canada

Dec 02, 2024

Talphera CFO Raffi Asadorian sells shares worth $118 - Investing.com India

Dec 02, 2024

Talphera CEO Vincent J. Angotti buys $3,649 in company stock - Investing.com India

Dec 02, 2024

Talphera CFO Raffi Asadorian sells shares worth $118 By Investing.com - Investing.com Canada

Dec 02, 2024

Nov 16, 2024

Talphera Third Quarter 2024 Earnings: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023) - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Talphera (FRA:R5XA) Inventories, Raw Materials & Components : €0.00 Mil (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024

Nov 14, 2024